Testing effectiveness (Phase 2)UnknownNCT05429905
What this trial is testing
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
Who this might be right for
Lymphoblastic LeukemiaLymphoblastic Leukemia, Acute, ChildhoodLymphoblastic Leukemia in Children+2 more
KK Women's and Children's Hospital 48